gip glp 1 medications The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 and Dual GIP/GLP-1 Agonists

Similarly the weight loss seen with Exenatide and some other early GLP-1 drugs was thought too limited to win approval for the treatment of obesity (Gilbert, Rosenthal, March 2024)

Continuing to follow the treatment plan is essential to maximizing the potential benefits of semaglutide GLP-1 in promoting weight loss

WEIGHT LOSS OPTIONS at Silva M.D

GLP-1s: Lower blood sugar Reduce appetiteso you eat less and feel fuller Promote healthy weight loss Improve metabolism Lower whole-body inflammationincluding that which affects your joints GLP-1s Target Both Metabolic and Inflammatory Pathways Recent research shows that GLP-1 medications can: Lower levels of inflammatory cytokines like TNF-alpha, IL-6, and IL-1 Restore a healthier gut microbiome and calm immune reactions Reduce fat-driven inflammationwhy losing just 510% of body weight improves autoimmune diseases Reverse insulin resistancea key link between metabolic and autoimmune disease Reduce oxidative stress, protecting organs and joint cartilage GLP-1s in RA, PsA, OA, and More: Evidence and Results Rheumatoid Arthritis Obesity increases RA risk and severity

Behavioral interventions have shown modest weight loss but are difficult to maintain

A sudden or excessive drop in blood sugar levels can disrupt blood flow, increasing the risk of ischemic events in the eye